Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11319355 Engineered IL-2 Fc fusion proteins

Patent 11319355 was granted and assigned to Xencor on May, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Xencor

Current Assignee

Xencor

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

113193550

Patent Inventor Names

John Desjarlais0

Rumana Rashid0

Rajat Varma0

Matthew Bernett0

Date of Patent

May 3, 2022

Patent Application Number

162068490

Date Filed

November 30, 2018

Patent Citations Received

‌

US Patent 12084484 Interleukin-2 agents and uses thereof

Patent Primary Examiner

CPC Code

The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11319355 Engineered IL-2 Fc fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API